Telix Pharmaceuticals Limited (ASX: TLX, Telix, the firm) today reported that it has agreed with Bayer AG (Bayer) to give Illuccix (TLX591-CDx, kit for the device of gallium Ga 68 gozetotide inoculation)[1] for the Phase III ARASTEP learning (ClinicalTrials.gov Identifier: NCT05794906). This global study goes into the success of Bayer’s androgen receptor inhibitor (ARi) divine plus androgen...
Telix to Supply Bayer with Illuccix for Worldwide Phase III Prostate Cancer Learning
T